Utilizing Estra-1,3,5,16-Tetraene Scaffold: Design and Synthesis of Nitric Oxide Donors as Chemotherapeutic Resistance Combating Agents in Liver Cancer
Molecules · 2023
DOI: 10.3390/molecules28062754 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecules, 2023. Verfasst von Mahrous A Abou-Salim und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Organic Chemistry, Faculty of Pharmacy, Al-Azhar University, Assiut 71524, Egypt. Hauptthemen laut MEDLINE: Antineoplastic Agents, Liver Neoplasms, Carcinoma, Hepatocellular. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 62 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministry of Higher Education, King Saud University, Egyptian Ministry of Higher Education.
Abstract (Originalsprache)
A new series of nitric oxide-releasing estra-1,3,5,16-tetraene analogs (NO-∆-16-CIEAs) was designed and synthesized as dual inhibitors for EGFR and MRP2 based on our previous findings on estra-1,3,5-triene analog NO-CIEA 17 against both HepG2 and HepG2-R cell lines. Among the target compounds, 14a (R-isomer) and 14b (S-isomer) displayed potent anti-proliferative activity against both HepG2 and HepG2-R cell lines in comparison to the reference drug erlotinib. Remarkably, compound 14a resulted in a prominent reduction in EGFR phosphorylation at a concentration of 1.20 µM with slight activity on the phosphorylation of MEK1/2 and ERK1/2. It also inhibits MRP2 expression in a dose-dependent manner with 24% inhibition and arrested the cells in the S phase of the cell cycle. Interestingly, compound 14a (estratetraene core) exhibited a twofold increase in anti-proliferative activity against both HepG2 and HepG2-R in comparison with the lead estratriene analog, demonstrating the significance of the designed ∆-16 unsaturation. The results shed a light on compound 14a and support further investigations to combat multidrug resistance in chemotherapy of hepatocellular carcinoma patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmaceutical Organic Chemistry, Faculty of Pharmacy, Al-Azhar University, Assiut 71524, Egypt.
- Department of Pharmaceutical Organic Chemistry, Faculty of Pharmacy, Cairo University, Cairo 11562, Egypt.
- Department of Pharmaceutical Chemistry, College of Pharmacy, King Saud University, Riyadh 11451, Saudi Arabia.
- Department of Chemistry and Biochemistry, South Dakota State University, Box 2202, Brookings, SD 57007, USA.
- Department of Organic and Medicinal Chemistry, Faculty of Pharmacy, University of Sadat City, Menoufia 32958, Egypt.
ORCID-Profile: Mahrous A Abou-Salim, Mohammed M Alanazi
Förderung
- Ministry of Higher Education
- King Saud University
- Egyptian Ministry of Higher Education
Zitieren
APA
Abou-Salim, M. A., Shaaban, M. A., Abd El Hameid, M. K., Alanazi, M. M., Halaweish, F., & Elshaier, Y. A. M. M. (2023). Utilizing Estra-1,3,5,16-Tetraene Scaffold: Design and Synthesis of Nitric Oxide Donors as Chemotherapeutic Resistance Combating Agents in Liver Cancer. Molecules. https://doi.org/10.3390/molecules28062754
Vancouver
Abou-Salim MA, Shaaban MA, Abd El Hameid MK, Alanazi MM, Halaweish F, Elshaier YAMM. Utilizing Estra-1,3,5,16-Tetraene Scaffold: Design and Synthesis of Nitric Oxide Donors as Chemotherapeutic Resistance Combating Agents in Liver Cancer. Molecules. 2023. doi:10.3390/molecules28062754
BibTeX
@article{AbouSalim2023,
author = {Abou-Salim, Mahrous A and Shaaban, Mohamed A and Abd El Hameid, Mohammed K and Alanazi, Mohammed M and Halaweish, Fathi and Elshaier, Yaseen A M M},
title = {Utilizing Estra-1,3,5,16-Tetraene Scaffold: Design and Synthesis of Nitric Oxide Donors as Chemotherapeutic Resistance Combating Agents in Liver Cancer},
journal = {Molecules},
year = {2023},
doi = {10.3390/molecules28062754}
}
EUVIMED